Kyriakos P. Papadopoulos
Clinical Trials of Texas(US)South Texas Accelerated Research Therapeutics(US)Center for Health Care Services(US)Center for Cancer Research(US)Center for Clinical Research (United States)(US)Texas Center for Infectious Disease(US)Start Treatment & Recovery Centers(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, CAR-T cell therapy research, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,359 cited
- → The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients(2019)1,249 cited
- → Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors(2015)774 cited
- → Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors(2016)742 cited
- → First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers(2019)575 cited
- → First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors(2011)541 cited